Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer
- 1 October 1998
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 34 (11) , 1693-1700
- https://doi.org/10.1016/s0959-8049(98)00209-3
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Dose-response is alive and well.Journal of Clinical Oncology, 1986
- Clinical Implications of Tumor-Cell HeterogeneityNew England Journal of Medicine, 1986
- Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancerBreast Cancer Research and Treatment, 1985
- Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacologyCancer, 1984
- Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group studyCancer, 1984
- A Controlled Trial of Adjuvant Chemotherapy with Melphalan Versus Cyclophosphamide, Methotrexate, and Fluorouracil for Breast CancerPublished by Springer Nature ,1984
- A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapyAmerican Journal of Clinical Oncology, 1982
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981
- Dose response evaluation of adriamycin in human neoplasiaCancer, 1977
- Drug dosage and remission duration in childhood lymphocytic leukemiaCancer, 1971